NCT00113932已完成2 期
UARK 2003-41: A Phase II Study of High-Dose Density Therapy With Tandem Autologous Transplants for Patients With Multiple Myeloma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 140
- 试验地点
- 2
- 主要终点
- To evaluate whether high-dose density treatment during the initial seven months, including tandem transplants within six months after starting therapy, results in superior event-free and overall survival rates as compared to historical controls.
研究概览
简要总结
The purpose of this study is to find out if treating multiple myeloma (MM) patients with more intense chemotherapy and autologous transplant (high dose density therapy) early in the disease course will result in better treatment outcomes compared to patients treated in the past.
详细描述
This study will evaluate whether high-dose density treatment during the initial seven months, including tandem transplants within six months after starting therapy, results in superior event-free and overall survival rates as compared to historical controls.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with symptomatic multiple myeloma, previously treated or untreated.
- •Patients previously untreated must not be eligible for UARK 2003-
- •Karnofsky performance score > 60%, unless due to MM
- •Patients must be <75 years of age at the time of registration
- •Patient must not have had a prior auto- or allotransplant
- •Patient must have signed an IRB-approved informed consent and understand the investigational nature of the study.
- •Negative serology for HIV.
- •Baseline studies within 60 days prior to registration; patients must not have a history of chronic obstructive or chronic restrictive pulmonary disease. Patients must have adequate pulmonary function studies > 50% of predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) > 50% of predicted. Patients unable to complete pulmonary function tests because of myeloma-related chest pain, must have a high resolution CT scan of the chest and must also have acceptable arterial blood gases defined as P02 greater than
- •Patients with recent (< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias are ineligible. Ejection fraction by ECHO or must be > 40% and must be performed within 60 days prior to registration, unless the patient has received chemotherapy within that period of time (dexamethasone and thalidomide excluded), in which case the LVEF must be repeated.
排除标准
- •Uncontrolled infection as defined in protocol section 5.1.11
- •Liver function abnormalities with total bilirubin more than twice the upper limit of normal or AST or ALT more than three times the upper limit of normal
- •Severe renal dysfunction, defined as a creatinine > 3mg/dl or a creatinine clearance of < 30ml/min
- •Significant neurotoxicity, defined as grade > 2 neurotoxicity per NCI Common Toxicity Criteria
- •Platelet count < 100,000/mm3, or ANC < 1,000/μl
- •POEMS Syndrome
- •Clinically significant hepatic dysfunction as noted by direct bilirubin or AST >3 times the upper normal limit or clinically significant concurrent hepatitis
- •New York Hospital Association (NYHA) Class III or Class IV heart failure
- •Myocardial infarction within the last 6 months
- •Patients with a history of treatment for clinically significant ventricular cardiac arrhythmias
- •Poorly controlled hypertension, diabetes mellitus, or other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
- •Pregnant or potential for pregnancy. Women of childbearing potential will have a pregnancy [β-HCG] test at screening, and will be required to use a medically approved contraceptive method. Pregnancy testing will be performed prior to administration of each dose of study drug
- •Breast-feeding women may not participate
- •Prior adriamycin exposure >450 mg/m2
结局指标
主要结局
To evaluate whether high-dose density treatment during the initial seven months, including tandem transplants within six months after starting therapy, results in superior event-free and overall survival rates as compared to historical controls.
时间窗: seven months
次要结局
- To evaluate the ability of pegfilgrastim to mobilize stem cells when administered following DTPACE in MM patients with active disease, compared to historical controls mobilized with DTPACE and either GM-CSF or G-CSF.(annually)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionMultiple MyelomaNCT00869232University of Arkansas90
招募中
1 期
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple MyelomaMultiple MyelomaNCT06185751Washington University School of Medicine25
进行中（未招募）
2 期
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior TherapyMyelomaNCT00871013University of Arkansas160
终止
1 期
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple MyelomaMultiple MyelomaNCT00039754Poniard Pharmaceuticals
终止
不适用
Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma RelapseMultiple Myeloma in RelapseNCT01794572Institut Cancerologie de l'Ouest13